SBD111

Bone loss is one of many health conditions exacerbated by inflammation. By harnessing the probiotic potential of fruit and vegetable microbes, Bondia™ targets the inflammatory signals that trigger bone degradation, while simultaneously strengthening the gut barrier to reduce further inflammation.

Findings

Through in vitro testing, Bondia™ was shown to increase gut barrier integrity, reduce inflammatory cytokine production from gut and immune cells, and reduce the production of osteoclasts, specialized bone resorbing cells, in culture.

Findings

Through preclinical testing, increased concentrations of Bondia™ were shown to improve bone maintenance, lessen inflammation, and reduce markers of osteoclasts. Together, these results are indicative of Bondia™’s ability to help maintain bone density.

Findings

Bondia™ was recently evaluated for efficacy in a large randomized, double-blind, placebo-controlled clinical food trial in 286 early postmenopausal women. The clinical trial is currently pending publication and peer review.

SBD121

Developed to be taken alongside the standard-of-care drug methotrexate, SBD121 is our Defined Microbial Assemblage (DMA™) that is currently undergoing clinical validation for its ability to improve arthritis symptoms and counteract the negative immune side effects of methotrexate.

Findings

Through in vitro tests, our candidate SBD121 was shown to increase gut barrier integrity, which can help the body better address the inflammation associated with rheumatoid arthritis.

Findings

Through preclinical testing, SBD121 was found to decrease the inflammatory signals that cause rheumatoid arthritis, as well as to reduce arthritis severity scores when consumed daily with methotrexate. Compared to methotrexate alone, usage of SBD121 in conjunction with methotrexate improved arthritis scores by approximately 50%.

Underway

SBD121 is currently being evaluated through a large randomized, double-blind, placebo-controlled clinical food trial featuring early-stage rheumatoid arthritis subjects. Subjects are intended to consume SBD121 twice-daily along with methotrexate. Through the clinical trial, SBD121 will be evaluated for its ability to increase rheumatoid arthritis scores, improve inflammatory signals and gut barrier function, and reduce joint inflammation and pain.